Tuesday, March 26, 2019

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Closes First Tranche of Private Placement; Plans to Release Early Efficacy Data of Lead Candidate in Combination Study


BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, this morning announced that it has closed the first tranche of a non-brokered private placement of up to 20,000,000 of its common shares, each at a price of C$0.10, for gross proceeds of up to approximately C$2,000,000. According to the update, the first tranche comprised of 7,500,000 common shares, each at a price of C$0.10, for gross proceeds of C$750,000. The closing of the second and final tranche of the offering is scheduled to occur in late March 2019. BriaCell intends to use net proceeds from the offering to finance its Phase IIa combination study of Bria-IMT(TM) with KEYTRUDA® by Merck & Co. Inc. (NYSE: MRK) in advanced breast cancer, as well as to pursue other research opportunities, for working capital and general corporate purposes. In addition, the company shared that it is finalizing analysis of the initial efficacy data of the first six patients in the combination study of its lead candidate, Bria-IMT(TM), with pembrolizumab (KEYTRUDA®) in advanced breast cancer.  BriaCell plans to announce this data via press release on April 3, 2019, concurrent with its poster presentation at the American Association for Cancer Research (“AACR”) Annual Meeting in Atlanta, Georgia.

To view the full press releases, visit http://ibn.fm/Wd1rA and http://ibn.fm/ZomEz

About BriaCell

BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.

NOTE TO INVESTORS: The latest news and updates relating to BCTXF are available in the company’s newsroom at www.ibn.fm/BCTXF

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php


No comments: